The Wall Street Journal
- Home
- HIMS
as of 03-13-2026 3:58pm EST
$24.72
+$0.85
+3.56%
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 3.6B | IPO Year: | 2019 |
| Target Price: | $28.21 | AVG Volume (30 days): | 31.7M |
| Analyst Decision: | Hold | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.51 | EPS Growth: | -3.77 |
| 52 Week Low/High: | $13.74 - $70.43 | Next Earning Date: | 05-26-2026 |
| Revenue: | $2,347,637,000 | Revenue Growth: | 59.00% |
| Revenue Growth (this year): | 19.27% | Revenue Growth (next year): | 17.96% |
| P/E Ratio: | 46.80 | Index: | N/A |
| Free Cash Flow: | 57.4M | FCF Growth: | -64.68% |
AI-Powered HIMS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 73.21%
73.21%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Hims & Hers Health Inc. (HIMS)
Boughton Soleil
Sell
Chief Legal Officer
HIMS Feb 27, 2026
Avg Cost/Share
$15.21
Shares
4,651
Total Value
$70,741.71
Owned After
440,972
SEC Form 4
Okupe Oluyemi
Sell
Chief Financial Officer
HIMS Feb 3, 2026
Avg Cost/Share
$26.44
Shares
5,262
Total Value
$139,107.81
Owned After
91,617
SEC Form 4
Okupe Oluyemi
Sell
Chief Financial Officer
HIMS Jan 20, 2026
Avg Cost/Share
$30.34
Shares
9,067
Total Value
$275,113.63
Owned After
91,617
SEC Form 4
Okupe Oluyemi
Sell
Chief Financial Officer
HIMS Jan 5, 2026
Avg Cost/Share
$33.79
Shares
9,070
Total Value
$306,452.63
Owned After
91,617
SEC Form 4
Okupe Oluyemi
Sell
Chief Financial Officer
HIMS Dec 22, 2025
Avg Cost/Share
$35.72
Shares
23,090
Total Value
$824,710.15
Owned After
91,617
SEC Form 4
Carroll Patrick Harrison
Sell
Chief Medical Officer
HIMS Dec 17, 2025
Avg Cost/Share
$36.71
Shares
10,021
Total Value
$367,870.91
Owned After
169,940
SEC Form 4
Becklund Irene
Sell
PAO
HIMS Dec 17, 2025
Avg Cost/Share
$36.71
Shares
8,411
Total Value
$308,767.81
Owned After
2,126
SEC Form 4
Chi Michael
Sell
Chief Operating Officer
HIMS Dec 17, 2025
Avg Cost/Share
$36.71
Shares
13,750
Total Value
$504,762.50
Owned After
305,161
SEC Form 4
Autor Deborah M.
Sell
Chief Policy Officer
HIMS Dec 17, 2025
Avg Cost/Share
$36.71
Shares
7,054
Total Value
$258,952.34
Owned After
6,175
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Boughton Soleil | HIMS | Chief Legal Officer | Feb 27, 2026 | Sell | $15.21 | 4,651 | $70,741.71 | 440,972 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Feb 3, 2026 | Sell | $26.44 | 5,262 | $139,107.81 | 91,617 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Jan 20, 2026 | Sell | $30.34 | 9,067 | $275,113.63 | 91,617 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Jan 5, 2026 | Sell | $33.79 | 9,070 | $306,452.63 | 91,617 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Dec 22, 2025 | Sell | $35.72 | 23,090 | $824,710.15 | 91,617 | |
| Carroll Patrick Harrison | HIMS | Chief Medical Officer | Dec 17, 2025 | Sell | $36.71 | 10,021 | $367,870.91 | 169,940 | |
| Becklund Irene | HIMS | PAO | Dec 17, 2025 | Sell | $36.71 | 8,411 | $308,767.81 | 2,126 | |
| Chi Michael | HIMS | Chief Operating Officer | Dec 17, 2025 | Sell | $36.71 | 13,750 | $504,762.50 | 305,161 | |
| Autor Deborah M. | HIMS | Chief Policy Officer | Dec 17, 2025 | Sell | $36.71 | 7,054 | $258,952.34 | 6,175 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 23, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 23, 2026 · 100% conf.
AI Prediction SELL
1D
-8.45%
$14.32
Act: -1.37%
5D
-11.12%
$13.91
Act: +4.60%
20D
-12.00%
$13.77
Price: $15.64 Prob +5D: 0% AUC: 1.000
0001773751-26-000019
hims-202602230001773751false00017737512026-02-232026-02-23
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 23, 2026
HIMS & HERS HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-38986 98-1482650
(State or other jurisdiction of incorporation)
(Commission File Number) (IRS Employer Identification No.)
2269 Chestnut Street, #523 94123
San Francisco , California (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (415) 851-0195
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading symbol Name of each exchange on which registered
Class A common stock, $0.0001 par value
HIMS
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 23, 2026, Hims & Hers Health, Inc. (the “Company”) issued a press release and a shareholder letter announcing its results of operations for the quarter and year ended December 31, 2025. Copies of the press release and the shareholder letter are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference in this Item 2.02. The information in this Current Report on Form 8-K and Exhibits 99.1 and 99.2 are being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1
Press Release dated February 23, 2026
99.2 Shareholder Letter dated February 23, 2026
104 Cover Page Interactive Data file (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HIMS & HERS HEALTH, INC.
DATE: February 23, 2026 By: /s/ Oluyemi Okupe
Oluyemi Okupe
Chief Financial Officer
(Principal Financial Officer)
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 3, 2025
0001773751-25-000352
hims-202511030001773751false00017737512025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 3, 2025
HIMS & HERS HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-3898698-1482650 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
2269 Chestnut Street, #523 94123 San Francisco,California (Zip Code) (Address of principal executive offices)
Registrant’s telephone number, including area code: (415) 851-0195
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Class A common stock, $0.0001 par valueHIMSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.Results of Operations and Financial Condition.
On November 3, 2025, Hims & Hers Health, Inc. (the "Company") issued a press release and a shareholder letter announcing its results of operations for the quarter ended September 30, 2025. Copies of the press release and the shareholder letter are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference in this Item 2.02. The information in this Current Report on Form 8-K and Exhibits 99.1 and 99.2 are being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1 Press Release dated November 3, 2025
99.2Shareholder Letter dated November 3, 2025
104Cover Page Interactive Data file (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HIMS & HERS HEALTH, INC.
DATE: November 3, 2025 By:/s/ Oluyemi Okupe Oluyemi Okupe Chief Financial Officer (Principal Financial Officer)
2025 Q2 Q2 2025 Earnings
8-K Aug 4, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 4, 2025
0001773751-25-000248
hims-202508040001773751false00017737512025-08-042025-08-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 4, 2025
HIMS & HERS HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-3898698-1482650 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
2269 Chestnut Street, #523 94123 San Francisco,California (Zip Code) (Address of principal executive offices)
Registrant’s telephone number, including area code: (415) 851-0195
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Class A common stock, $0.0001 par valueHIMSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.Results of Operations and Financial Condition.
On August 4, 2025, Hims & Hers Health, Inc. (the "Company") issued a press release announcing its results of operations for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 2.02. The information in this Current Report on Form 8-K and Exhibit 99.1 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01.Other Events.
Hims & Hers Health’s Disclosure Channels To Disseminate Information
Investors of the Company and others should note that we announce information to the public about the Company, the products and services available on the Company’s platform, and other updates regarding the Company through a variety of channels, including the Company’s websites, press releases, SEC filings, public conference calls, webcasts, blogs and various social media accounts, including our and our Chief Executive Officer’s accounts, in order to achieve broad, non-exclusionary distribution of information to the public. We encourage our investors and others to review the information we make public on the locations below as such information could be deemed to be material information. Please note that this list may be updated from time to time.
Interested in keeping up with Hims & Hers Health?
For more information from the Company, please visit or follow: •the Company’s websites at hims.com and forhers.com; •the Company’s investor relations website at investors.hims.com; •the Company’s news website at news.hims.com; •the Company’s and Andrew Dudum’s X accounts at x.com/wearehims, x.com/wearehers, and x.com/AndrewDudum; and •the Company’s LinkedIn accounts at linkedin.com/company/hims-&-hers and linkedin.com/showcase/h-h-corporate-affairs.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1 Press Release dated August 4, 2025
99.2Shareholder Letter dated August 4, 2025
104Cover Page Interactive Data file (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HIMS & HERS HEALTH, INC.
DATE: August 4, 2025 By:/s/ Oluyemi Okupe Oluyemi Okupe Chief Financial Officer (Principal Financial Officer)
Latest Hims & Hers Health Inc. News
HIMS Breaking Stock News: Dive into HIMS Ticker-Specific Updates for Smart Investing
The Wall Street Journal
Hims & Hers Stock Surges as Novo Nordisk Deal Ends Legal Dispute
Investor's Business Daily
Hims And Hers Surges 40% On Deal To Sell Novo Nordisk Obesity Drugs
MT Newswires
Sector Update: Health Care
Compare HIMS vs Leading Stocks
See how HIMS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HIMS Hims & Hers Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.